285 related articles for article (PubMed ID: 34504264)
1. The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
Ngamkam J; Vadcharavivad S; Areepium N; Auamnoy T; Takkavatakarn K; Katavetin P; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Sci Rep; 2021 Sep; 11(1):18006. PubMed ID: 34504264
[TBL] [Abstract][Full Text] [Related]
2. The Calcium-Sensing Receptor Gene Polymorphism rs1801725 and Calcium-Related Phenotypes in Hemodialysis Patients.
Grzegorzewska AE; Bednarski D; Świderska M; Mostowska A; Jagodziński PP
Kidney Blood Press Res; 2018; 43(3):719-734. PubMed ID: 29763933
[TBL] [Abstract][Full Text] [Related]
3. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
[TBL] [Abstract][Full Text] [Related]
4. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.
Moe SM; Wetherill L; Decker BS; Lai D; Abdalla S; Long J; Vatta M; Foroud TM; Chertow GM
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1128-1138. PubMed ID: 28630081
[TBL] [Abstract][Full Text] [Related]
5. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients].
Massimetti C; Bellasi A; Feriozzi S
G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530156
[No Abstract] [Full Text] [Related]
6. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Więcek A
Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
[TBL] [Abstract][Full Text] [Related]
7. Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis.
Imafuku T; Tanaka M; Tokunaga K; Miyamura S; Kato H; Tanaka S; Nakano T; Hirata K; Kadowaki D; Maeda H; Matsushita K; Otagiri M; Komaba H; Fukagawa M; Watanabe H; Maruyama T
Biol Pharm Bull; 2020; 43(10):1583-1590. PubMed ID: 32999168
[TBL] [Abstract][Full Text] [Related]
8. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl.
Rothe HM; Shapiro WB; Sun WY; Chou SY
Pharmacogenet Genomics; 2005 Jan; 15(1):29-34. PubMed ID: 15864123
[TBL] [Abstract][Full Text] [Related]
9. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
[TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients.
Zawierucha J; Małyszko J; Małyszko JS; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
Pol Arch Intern Med; 2017 Dec; 127(12):840-845. PubMed ID: 29067991
[TBL] [Abstract][Full Text] [Related]
11. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
[TBL] [Abstract][Full Text] [Related]
12. Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment.
Kuczera P; Adamczak M; Wiecek A
Kidney Blood Press Res; 2016; 41(1):1-8. PubMed ID: 26751580
[TBL] [Abstract][Full Text] [Related]
13. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
[TBL] [Abstract][Full Text] [Related]
14. Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients.
Grzegorzewska AE; Paciorkowski M; Mostowska A; Frycz B; Warchoł W; Stolarek I; Figlerowicz M; Jagodziński PP
Sci Rep; 2016 Oct; 6():35188. PubMed ID: 27739473
[TBL] [Abstract][Full Text] [Related]
15. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
[TBL] [Abstract][Full Text] [Related]
16. [Gene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patients].
Grzegorzewska AE; Ostromecki G
Przegl Lek; 2013; 70(9):735-8. PubMed ID: 24455835
[TBL] [Abstract][Full Text] [Related]
17. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
[TBL] [Abstract][Full Text] [Related]
19. Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism.
Okuno S; Inaba M; Ishimura E; Nakatani S; Chou H; Shoji S; Yamakawa T
Nephron; 2019; 142(2):106-113. PubMed ID: 30712039
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature.
Forman TE; Niemi AK; Prahalad P; Shi RZ; Nally LM
J Pediatr Endocrinol Metab; 2019 Mar; 32(3):305-310. PubMed ID: 30730839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
